Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Nature Reviews. Microbiology|November 21, 2024
Hepatitis B and D virus entryKoichi Watashi, Kaho Shionoya, Chisa Kobayashi, et al.Antiviral Research|April 24, 2026
Receptor recognition of hepatitis B and D viruses: Structural insight and its application to drug discoveryKaho Shionoya, Chisa Kobayashi, Kayo Matsuzawa, et al.Plos Pathogens|January 16, 2026
Structural mapping of NTCP distinguishes its dual functionality as a hepatitis B virus receptor and bile acid transporterKayo Matsuzawa, Toru Ekimoto, Chisa Kobayashi, et al.Plos Biology|July 31, 2020
Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemmaShoya Iwanami, Kosaku Kitagawa, Hirofumi Ohashi, et al.Frontiers in Microbiology|May 17, 2021
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitroKaho Shionoya, Masako Yamasaki, Shoya Iwanami, et al.Nature Communications|October 25, 2024
Structural basis for hepatitis B virus restriction by a viral receptor homologueKaho Shionoya, Jae-Hyun Park, Toru Ekimoto, et al.Nature Communications|January 30, 2026
Multistep receptor binding of the hepatitis B virus preS1 domainChisa Kobayashi, Toru Ekimoto, Koji Ooka, et al.Plos Pathogens|May 3, 2023
An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activityPeter A C Wing, Nathalie M Schmidt, Rory Peters, et al.Microbiology Spectrum|July 6, 2023
Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus AgentsTakayuki Hishiki, Takeshi Morita, Daisuke Akazawa, et al.Antiviral Research|July 7, 2022
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, et al.Pageof 2